FDA Expedited Drug Program Raises Safety Concerns for Obesity Meds

FDA's Expedited Drug Review Program Sparks Internal Alarms

The Food and Drug Administration's new effort to shorten drug reviews to as little as one month for medicines supporting U.S. national interests is raising significant concerns among agency staff. Seven current or former staffers report anxiety over potential violations of legal, ethical, and scientific standards used to evaluate drug safety and effectiveness.

This Commissioner's National Priority Voucher program has led to confusion, especially amid recent layoffs and leadership changes at the FDA.

Questions Over Authority and Traditional Processes

High-level FDA officials question who has legal authority to approve drugs under this program. Traditionally, approvals are handled by review scientists and supervisors, not senior leaders.

Drug reviewers report receiving minimal details on program operations. Some staff working on a highly anticipated anti-obesity pill were instructed to skip certain regulatory steps to meet tight deadlines.

Expert Warnings on Review Timelines

FDA drug reviews, already the world's fastest at six to 10 months, face criticism for further acceleration. "The concept of doing a review in one to two months just does not have scientific precedent," said Dr. Aaron Kesselheim, professor at Harvard Medical School.

"FDA cannot do the same detailed review that it does of a regular application in one to two months, and it doesn't have the resources to do it," Kesselheim added.

Safety Delays and Obesity Drug Pressures

Recent reports indicate FDA officials delayed reviews of two drugs in the program due to safety concerns, including the death of a patient on one medication. This underscores risks in rushed processes for high-stakes therapies like obesity drugs.

The program prioritizes "gold standard scientific review" for effective treatments, but staff worry about deviations.

Focus on Eli Lilly and Novo Nordisk Obesity Drugs

FDA staff expedited vouchers for Eli Lilly and Novo Nordisk after pricing announcements on their popular obesity drugs, such as those akin to Ozempic, Wegovy, and Mounjaro. Reviewers scrambled to vet applications under pressure.

• These GLP-1 medications and similar therapies are central to weight management.
• Expedited processes risk political influence over objective standards.

"It's extraordinary to have such an opaque application process, one that is obviously susceptible to politicization," said Paul Kim, former FDA attorney.

Lack of Formal Regulations Fuels Concerns

Unlike congressionally approved FDA speed-up programs with detailed regulations, this initiative is outlined mainly on an agency website. Drugmakers apply via a 350-word statement of interest.

Senior leaders, including Dr. Vinay Prasad, FDA's top medical officer, have directly contacted drugmakers about vouchers, creating procedural quandaries for staff.

Leadership Declines and Legal Risks

The program's legality prompted former drug director Dr. George Tidmarsh to decline sign-offs, leading to his resignation. Principal deputy commissioner Dr. Sara Brenner also refused after legal review.

Currently, deputy chief medical officer Dr. Mallika Mundkur handles approvals under Prasad. Final sign-off carries legal risks, certifying drug safety and effectiveness amid potential future lawsuits.

Approvals now involve committee votes by senior leaders, bypassing staff reviewers. "It is a complete reversal from the normal review process, which is traditionally led by the scientists immersed in the data," Kesselheim noted.

Program Expansion Adds Strain

Initially a pilot for five drugs, the program has issued 18 vouchers, with more pending. This strains the drug center, where 20% of staff departed recently.

Early selections came from career staffers choosing quickly vet-able drugs, but now senior officials lead, sometimes without staff knowledge.

Eli Lilly Anti-Obesity Pill Review Pressures

For Eli Lilly's oral anti-obesity pill, executives pushed for two-month approval, skipping the standard 60-day prefiling check. The agency compromised on a two-week period.

Lilly CEO David Ricks expects Q2 approval. Reviewers faced missing chemistry data but were told to proceed if science seemed sound, overriding regulations.

Experts warn this inverts proper FDA processes, where regulations confirm safety. Rushed approvals risk invalidation by future leaders.

"They are fundamentally changing the application of the standards, but the underlying law remains what it is," Kesselheim said. "The hope is that one day we will return to these scientifically sound, legally sound principles."

Implications for GLP-1 and Weight Management

For patients using GLP-1 medications like semaglutide and tirzepatide, expedited reviews heighten vigilance needs. Evidence-based weight management relies on thorough safety vetting to avoid adverse events.